1 ich q9: quality risk management h. gregg claycamp, ph.d. office of new animal drug evaluation...

25
1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation [email protected] CDER ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE (ACPS) October 5-6, 2006 Rockville, MD

Upload: geoffrey-colin-preston

Post on 22-Dec-2015

228 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: 1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation gregg.claycamp@fda.hhs.gov CDER ADVISORY COMMITTEE FOR

1

ICH Q9: Quality Risk Management

H. Gregg Claycamp, Ph.D.Office of New Animal Drug Evaluation

[email protected]

CDER ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE (ACPS)

October 5-6, 2006 Rockville, MD

Page 2: 1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation gregg.claycamp@fda.hhs.gov CDER ADVISORY COMMITTEE FOR

2

Quality Risk Management

Claycamp 2006

Why was ICH Q9 needed?

To ensure a common understanding of Quality Risk Management (QRM) by both industry and regulators • To facilitate moving to the “Desired State”

• To facilitate communication and transparency

• To move from ‘fire fighting’ to management of risk

ICH Q9 explains• A common language and process

• Potential methodologies for QRM

• Where QRM can add value

Page 3: 1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation gregg.claycamp@fda.hhs.gov CDER ADVISORY COMMITTEE FOR

3

Quality Risk Management

Claycamp 2006

What’s in Quality Risk Management?

Q9 has broad risk concepts and principles Principles for implementation Elements of Risk Assessment/Management

Processes Does not discuss a single tool, but “The Right

Tool for the Job” approach Risk Management Tools

• High-level (Ideas and Concepts)

• Mid-Level (Quantitative and Qualitative)

• Low-Level (Real numbers and real time)

Page 4: 1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation gregg.claycamp@fda.hhs.gov CDER ADVISORY COMMITTEE FOR

4

Quality Risk Management

Claycamp 2006

What’s not in ICH Q9 …

A “cookbook” for risk management

A specific prescription for your risk management program

An exhaustive treatment of theory

An exhaustive list of methods and tools

Page 5: 1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation gregg.claycamp@fda.hhs.gov CDER ADVISORY COMMITTEE FOR

5

Quality Risk Management

Claycamp 2006

Q9’s Sample Process

Risk Review

Risk Assessment

Risk Evaluationunacceptable

Risk Control

Risk Analysis

Risk Reduction

Risk Identification

Review Events

Risk Acceptance

InitiateQuality Risk Management Process

Output / Result of theQuality Risk Management Process

Ris

k M

an

ag

em

en

t To

olsR

isk

Co

mm

un

ica

tio

n

Page 6: 1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation gregg.claycamp@fda.hhs.gov CDER ADVISORY COMMITTEE FOR

6

Quality Risk Management

Claycamp 2006

QRM is not a Single ProcessStart

End

Risk identification

Risk analysis

Etc.

Process-step

Decision

Feedback procedure

Start

End

Start

End

Sub-process

Sub-Sub-process

Page 7: 1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation gregg.claycamp@fda.hhs.gov CDER ADVISORY COMMITTEE FOR

7

Quality Risk Management

Claycamp 2006

Different Meanings of “Risk”

Individual: Risk is a cognitive and emotional response to expected loss.

Society: Risk is a societal expression of expected harm tempered by expected benefits.

Organizations: Risk is a combination of the probability of occurrence and severity of selected harms.

Technical: Risk is usually based on the expected value of the conditional probability of the event occurring times the consequence of the event given that it has occurred.

Page 8: 1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation gregg.claycamp@fda.hhs.gov CDER ADVISORY COMMITTEE FOR

8

Quality Risk Management

Claycamp 2006

Q9 Overarching Principles

“The evaluation of the risk to quality should be based on scientific knowledge and ultimately link back to the protection of the patient; and

The level of effort, formality, and documentation of the quality risk management process should be commensurate with the level of risk.”

Page 9: 1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation gregg.claycamp@fda.hhs.gov CDER ADVISORY COMMITTEE FOR

9

Quality Risk Management

Claycamp 2006

Concept: Link Back to Patient Risk

Process

Materials

Design

Manufacturing

Distribution

Patient

Facilities

Opportunities to impact risk using quality risk

management

Page 10: 1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation gregg.claycamp@fda.hhs.gov CDER ADVISORY COMMITTEE FOR

10

Quality Risk Management

Claycamp 2006

QRM and the Design Space

What is the chance (probability) of “falling outside” of the design space per unit time?

Risk analysts estimate probabilities of being outside (or inside!) of design limits, given various scenarios.

Design parameters and their intersection in a “design space” concept

v1

v2

v3

design space

Page 11: 1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation gregg.claycamp@fda.hhs.gov CDER ADVISORY COMMITTEE FOR

11

Quality Risk Management

Claycamp 2006

“Systems” thinking and methods!

A systematic process for the assessment, control, communication and review of risks to the quality of the drug product across the product lifecyle.

QRM: Another Systems Approach

Page 12: 1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation gregg.claycamp@fda.hhs.gov CDER ADVISORY COMMITTEE FOR

12

Quality Risk Management

Claycamp 2006

“Risk Management” is Universal

Company

Strategic Risks Operational Risks Financial Risks Compliance Risks

Competitor Advantage

Company Viability

Shareholder Harm

Patient Harm

ICH Q9 Impact

Page 13: 1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation gregg.claycamp@fda.hhs.gov CDER ADVISORY COMMITTEE FOR

13

Quality Risk Management

Claycamp 2006

Severity and Probability Risk

Increasing Severity of Harm/Consequence

Incr

easi

ng P

roba

bilit

y of

O

ccur

renc

e

Low Risk

Medium Risk

High Risk

Page 14: 1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation gregg.claycamp@fda.hhs.gov CDER ADVISORY COMMITTEE FOR

14

Quality Risk Management

Claycamp 2006

Tools for Risk Management

ICH Q9 Includes an Annex of Tools

Page 15: 1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation gregg.claycamp@fda.hhs.gov CDER ADVISORY COMMITTEE FOR

15

Quality Risk Management

Claycamp 2006

“High-Level” Tools

Often rely mixed kinds of information:• Quantitative

• Qualitative

• Expert judgment

Focus on systematic thinking:• Define the risk question

• Organize information under categories, attributes

• Build decision making paths

Page 16: 1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation gregg.claycamp@fda.hhs.gov CDER ADVISORY COMMITTEE FOR

16

Quality Risk Management

Claycamp 2006

Examples of implementation: FDA

CDER/ORA Site Selection process for GMP inspections

CVM pre-approval decision support system (PAIDSS)

Other efforts in progress

Page 17: 1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation gregg.claycamp@fda.hhs.gov CDER ADVISORY COMMITTEE FOR

17

Quality Risk Management

Claycamp 2006

Qualitative Risk Estimation

Health

Severity Scale

Probability of Occurrence

Very Low Low Medium High

Very High

Death Medium Medium High High High

Hospitalization Low Medium Medium High High

Acute Illness Low Medium Medium High High

Worry Low Low Low Medium Medium

SAMPLE TABLE ONLY

Low Risk

Medium Risk

High RiskA

B

C

Page 18: 1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation gregg.claycamp@fda.hhs.gov CDER ADVISORY COMMITTEE FOR

18

Quality Risk Management

Claycamp 2006

Risk Ranking –High Level

Process

Facility

Product

1. Site M

2. Site T

3. Site C

4. Site D

5. Site X

6. Site A

Scored and Prioritized Under Multiple Criteria

(Risk Ranking)

SAMPLE CHART

Page 19: 1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation gregg.claycamp@fda.hhs.gov CDER ADVISORY COMMITTEE FOR

19

Quality Risk Management

Claycamp 2006

Mid-Level: Combinations of Methods

More formula-driven than High-level tools and approaches

Expert-driven qualitative with some data • FME(C)A

• Decision analytic methods

Limitations• Which experts?

• Risk-analytical methods

• Sorting value- and perception-driven assessments with quantitative variables

Page 20: 1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation gregg.claycamp@fda.hhs.gov CDER ADVISORY COMMITTEE FOR

20

Quality Risk Management

Claycamp 2006

FME(C)A

10987654321

Sev

erity

of

Eff

ect

10987654321O

ccur

renc

e P

roba

bilit

y

S

CriticalityS x O

123456789

10Det

ectio

n*

“SOD” or “Risk

Number”

O S x O x D

*Higher detection ability lowers risk score.

Page 21: 1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation gregg.claycamp@fda.hhs.gov CDER ADVISORY COMMITTEE FOR

21

Quality Risk Management

Claycamp 2006

FME(C)A—Intermediate Tool

SAMPLE CHART

Page 22: 1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation gregg.claycamp@fda.hhs.gov CDER ADVISORY COMMITTEE FOR

22

Quality Risk Management

Claycamp 2006

Present Status of the Guideline

Published as US Guidance, June 2006• http://www.fda.gov/cder/guidance/7153fnl.htm

Judging by industry and regulatory conferences, workshops, publications: interest in Q9 remains high

Some members of the ICH EWG compiled presentations for information. Now available on ICH website: • http://www.ich.org/cache/compo/276-254-1.html

Page 23: 1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation gregg.claycamp@fda.hhs.gov CDER ADVISORY COMMITTEE FOR

23

Quality Risk Management

Claycamp 2006

Next Steps?

From great ideas to practice—how? Both industry and regulators want to

know• Which risks firsts?

• Which tools are best?

• How will I know “good” from “bad” risk management?

• Do we need dept./divisions of risk managers?

Page 24: 1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation gregg.claycamp@fda.hhs.gov CDER ADVISORY COMMITTEE FOR

24

Quality Risk Management

Claycamp 2006

Examples of Implementation: Industry

Many presentations at conferences showing examples of:• Failure modes and effects analysis (FMEAs)

• Multivariate models (QC/QA integration)

• Systems design, modeling and application are readily adaptable to QRM approaches

Page 25: 1 ICH Q9: Quality Risk Management H. Gregg Claycamp, Ph.D. Office of New Animal Drug Evaluation gregg.claycamp@fda.hhs.gov CDER ADVISORY COMMITTEE FOR

25

Quality Risk Management

Claycamp 2006

Keys to Implementation

Key to implementation: the systems approaches in Q8-Q9-Q10 leverage the best parts of existing knowledge bases and expertise for systematic control of risks to pharmaceutical quality.• Gregg’s Pareto principle for QRM: “More than

80% of the expertise for a Quality Risk Management program exists among the domain --i.e., not risk-- experts.”